Findings seen in children with pancreatic sufficient acute recurrent pancreatitis or chronic pancreatitis<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 16, 2024 (HealthDay News) — Use of pancreatic enzyme therapy (PERT) is associated with a reduction in the incidence rate of acute pancreatitis (AP) among children with pancreatic sufficient acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), according to a study published online March 22 in the American Journal of Gastroenterology<\/em>.<\/p>\n A. Jay Freedman, M.D., from Nationwide Children’s Hospital at The Ohio State University College of Medicine in Columbus, and colleagues conducted a retrospective cohort study to examine the impact of PERT among children with pancreatic sufficient ARP or CP. Clinical outcomes were compared for those receiving and not receiving PERT.<\/p>\n The researchers found that 76 percent of the 356 pancreatic sufficient participants had ARP and 17 percent received PERT. During a mean follow-up of 2.1 years, 42 percent of those on PERT did not have a subsequent AP episode. The likelihood of having an AP episode after starting PERT was lower for children with SPINK1<\/em> mutation and those with ARP versus CP. The mean AP annual incidence rate decreased from 3.14 to 0.71 after initiation of PERT.<\/p>\n “Our findings not only highlight PERT’s role in significantly reducing the incidence of acute pancreatitis episodes among children with recurrent or chronic pancreatitis but also underscore the importance of a tailored treatment approach based on genetic markers,”\u00a0coauthor Matthew Giefer, M.D., from Ochsner Children’s Hospital in New Orleans, said in a statement.<\/p>\n Several authors disclosed ties to the pharmaceutical, nutritional, and medical technology industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n